Oncology at Renji Hospital Shanghai | CMCS

Precision Cancer Medicine at One of Shanghai's Premier Hospitals

The Department of Oncology at Renji Hospital — affiliated with Shanghai Jiao Tong University School of Medicine — is one of Shanghai's most distinguished oncology centers, with a national reputation for excellence in precision oncology, immunotherapy, targeted therapy, and the multidisciplinary management of gastrointestinal cancers, hepatobiliary cancers, breast cancer, lung cancer, and other solid tumors. The department combines outstanding clinical expertise with a world-class research program and a fully integrated multidisciplinary approach, offering international patients access to some of China's most eminent oncologists and the latest evidence-based systemic therapies and clinical trials.

For international patients with advanced cancer seeking expert systemic therapy, a second opinion on treatment strategy, access to novel targeted agents or immunotherapy, or enrollment in clinical trials — Renji Hospital's oncology department offers an unparalleled combination of clinical expertise, research leadership, and multidisciplinary integration. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their care journey at Renji Hospital.

About the Department

Renji Hospital's oncology department is a national key clinical specialty operating dedicated oncology inpatient wards, a comprehensive chemotherapy and immunotherapy infusion center, a precision oncology and molecular tumor board, subspecialty clinics for gastrointestinal cancers, hepatobiliary cancers, breast cancer, and lung cancer, and one of Shanghai's most active cancer clinical trial programs. The department works in close collaboration with all surgical departments, gastroenterology, liver transplantation, radiation oncology, pathology, and molecular diagnostics through fully integrated multidisciplinary tumor boards.

Faculty members publish regularly in leading oncology journals including Journal of Clinical Oncology, Annals of Oncology, Lancet Oncology, Hepatology, and Journal of Hepatology.

Cancer-Specific Expertise

Hepatocellular Carcinoma (HCC)

Renji Hospital's HCC program is one of China's most comprehensive, uniquely integrating oncology, hepatology, interventional radiology, and liver transplantation:

• Early HCC — Surgical resection; ablation (RFA, MWA); liver transplantation within Milan/UCSF criteria; TACE as bridge to transplantation
• Intermediate HCC (BCLC-B) — TACE; HAIC (hepatic arterial infusion chemotherapy with FOLFOX); TACE + systemic therapy combinations; Y-90 radioembolization
• Advanced HCC (BCLC-C) — Atezolizumab + bevacizumab (IMbrave150 — first-line standard); sintilimab + bevacizumab biosimilar; tremelimumab + durvalumab (HIMALAYA); lenvatinib; sorafenib; HAIC + systemic therapy for high tumor burden
• HCC Downstaging — TACE/HAIC/systemic therapy for tumor downstaging to transplant criteria; response-guided listing
• Second-Line HCC — Regorafenib; cabozantinib; ramucirumab (AFP ≥4); nivolumab; pembrolizumab
• HBV-Associated HCC — Antiviral therapy (tenofovir, entecavir) throughout systemic treatment; HBV reactivation prevention

Cholangiocarcinoma & Biliary Tract Cancer

• Resectable Cholangiocarcinoma — Surgical resection coordination; adjuvant capecitabine
• Advanced Biliary Tract Cancer — Gemcitabine + cisplatin + durvalumab (TOPAZ-1 — first-line standard); gemcitabine + cisplatin + tremelimumab + durvalumab; FOLFOX second-line
• IDH1-Mutated Cholangiocarcinoma — Ivosidenib (ClarIDHy trial)
• FGFR2-Fused Cholangiocarcinoma — Pemigatinib; infigratinib; futibatinib; RLY-4008 for FGFR2 inhibitor-resistant disease
• HER2-Amplified Biliary Tract Cancer — Trastuzumab + pertuzumab; zanidatamab; T-DXd
• BRAF V600E Cholangiocarcinoma — Dabrafenib + trametinib

Pancreatic Cancer

• Resectable Pancreatic Cancer — Surgical resection coordination (Whipple/distal pancreatectomy); adjuvant FOLFIRINOX or gemcitabine + capecitabine
• Borderline Resectable & Locally Advanced PDAC — FOLFIRINOX or gemcitabine + nab-paclitaxel induction; conversion surgery for responders; SBRT consolidation
• Metastatic PDAC — FOLFIRINOX; gemcitabine + nab-paclitaxel; olaparib maintenance for BRCA-mutated; KRAS G12D inhibitors (BI 1701963, HRS-4642) in clinical trials
• Pancreatic Neuroendocrine Tumors (pNET) — Somatostatin analogues (octreotide LAR, lanreotide); everolimus; sunitinib; lutetium-177 DOTATATE (PRRT) for SSTR-positive pNET; surgical resection

Colorectal Cancer

• Metastatic Colorectal Cancer (mCRC) — FOLFOX/FOLFIRI + bevacizumab or cetuximab/panitumumab (RAS/BRAF WT); encorafenib + cetuximab for BRAF V600E mCRC; trastuzumab + pertuzumab or T-DXd for HER2-amplified mCRC; pembrolizumab for MSI-H/dMMR mCRC (first-line); fruquintinib; trifluridine/tipiracil + bevacizumab
• Liver-Limited Metastatic CRC — Conversion chemotherapy; hepatic resection coordination; HAI (hepatic arterial infusion) chemotherapy; Y-90 radioembolization
• Rectal Cancer — Total neoadjuvant therapy (TNT); watch-and-wait for complete clinical response; surgical coordination

Gastric & GEJ Cancer

• Locally Advanced Gastric Cancer — Perioperative FLOT; neoadjuvant SOX/XELOX; surgical coordination
• Metastatic Gastric Cancer — Nivolumab + chemotherapy (CheckMate 649); pembrolizumab + chemotherapy (KEYNOTE-811); trastuzumab + chemotherapy for HER2-positive; T-DXd for HER2-positive second-line; zolbetuximab + FOLFOX/CAPOX for CLDN18.2-positive; ramucirumab + paclitaxel second-line

Breast Cancer

• HR-Positive/HER2-Negative — CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib); alpelisib for PIK3CA-mutated; capivasertib + fulvestrant for PIK3CA/AKT1/PTEN-altered; elacestrant for ESR1-mutated; inavolisib combinations
• HER2-Positive — Trastuzumab + pertuzumab; T-DM1; T-DXd; tucatinib + capecitabine + trastuzumab for brain metastases
• Triple-Negative Breast Cancer (TNBC) — Pembrolizumab + chemotherapy; sacituzumab govitecan; olaparib/talazoparib for BRCA-mutated; datopotamab deruxtecan

Lung Cancer

• EGFR-Mutated NSCLC — Osimertinib; amivantamab + lazertinib for osimertinib-resistant; patritumab deruxtecan for HER3-expressing
• ALK/ROS1-Positive NSCLC — Alectinib, brigatinib, lorlatinib; entrectinib for ROS1
• Immunotherapy for NSCLC — Pembrolizumab monotherapy for PD-L1 ≥50%; pembrolizumab + chemotherapy; nivolumab + ipilimumab; atezolizumab + bevacizumab + chemotherapy; durvalumab consolidation for stage III
• KRAS G12C NSCLC — Sotorasib; adagrasib

Precision Oncology & Molecular Tumor Board

• Comprehensive Genomic Profiling (CGP) — NGS panel testing for actionable mutations, fusions, TMB, and MSI; liquid biopsy for treatment monitoring and resistance detection
• Molecular Tumor Board — Weekly multidisciplinary review of complex molecular profiling results; off-label targeted therapy recommendations; clinical trial eligibility assessment
• Tumor-Agnostic Therapies — Pembrolizumab for TMB-high and MSI-H/dMMR; larotrectinib/entrectinib for NTRK fusions; selpercatinib for RET fusions; dabrafenib + trametinib for BRAF V600E

HAIC Program — A Renji Specialty

Renji Hospital is one of China's most experienced centers for hepatic arterial infusion chemotherapy (HAIC) with FOLFOX, a locoregional treatment approach that delivers high-dose chemotherapy directly to liver tumors via the hepatic artery. HAIC has demonstrated superior response rates compared to TACE for large or multifocal HCC and is increasingly used in combination with systemic immunotherapy and anti-angiogenic agents for conversion therapy and downstaging.

Why International Patients Choose Renji Oncology

• HCC & Liver Cancer Expertise — Unique integration of oncology, hepatology, HAIC, and liver transplantation for comprehensive HCC management
• Biliary Tract Cancer Leadership — FGFR2, IDH1, HER2, and BRAF-targeted therapy for cholangiocarcinoma
• HAIC Program — One of China's most experienced HAIC centers for large and multifocal HCC
• Precision Oncology — Comprehensive molecular tumor board with CGP and liquid biopsy
• Clinical Trial Access — Active participation in national and international oncology trials including novel KRAS inhibitors and next-generation ADCs
• Cost-Effectiveness — World-class cancer medicine at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your cancer diagnosis, pathology reports, molecular profiling results, imaging, and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate oncologist based on your tumor type and molecular profile.
4. Molecular Tumor Board Submission — Where appropriate, we facilitate pre-arrival case review by Renji's molecular tumor board.
5. Priority Scheduling — We secure a consultation with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near Renji Hospital, and Shanghai airport transfers.
7. Treatment Coordination — Full coordination of molecular profiling, imaging, infusion scheduling, and clinical trial enrollment.
8. Post-Treatment Follow-Up — Treatment response assessment, molecular profiling report translation, and remote follow-up after you return home.

Book a Consultation

If you are seeking expert oncology care in Shanghai — whether for HCC, cholangiocarcinoma, pancreatic cancer, colorectal cancer, gastric cancer, breast cancer, lung cancer, or a second opinion — CMCS can arrange a specialist consultation with Renji Hospital's oncology team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com